Literature DB >> 21228057

Meta-analysis finds screening for prostate cancer with PSA does not reduce prostate cancer-related or all-cause mortality but results likely due to heterogeneity - the two highest quality studies identified do find prostate cancer-related mortality reductions.

Monique J Roobol1, Sigrid Carlsson, Jonas Hugosson.   

Abstract

Entities:  

Year:  2011        PMID： 21228057     DOI： 10.1136/ebm1165

Source DB:  PubMed          Journal:  Evid Based Med        ISSN： 1356-5524


× No keyword cloud information.
  4 in total

1.  Prostate-specific antigen screening can be beneficial to younger and at-risk men.

Authors:  Monique J Roobol; Chris H Bangma; Stacy Loeb
Journal:  CMAJ       Date:  2012-05-07       Impact factor: 8.262

2.  [Reply to: PSA screening : Possible uses and harm by N. Keller, M. Jenny, G. Gigerenzer, R. Ablin].

Authors:  Carsten Stephan; Thorsten Schlomm; Klaus Jung
Journal:  Urologe A       Date:  2018-07       Impact factor: 0.639

3.  Prostate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa).

Authors:  Carsten Stephan; Harry Rittenhouse; Xinhai Hu; Henning Cammann; Klaus Jung
Journal:  EJIFCC       Date:  2014-04-28

4.  Prostate-specific Antigen Density Variation Rate as a Potential Guideline Parameter for Second Prostate Cancer Detection Biopsy.

Authors:  Gan-Sheng Xie; Jin-Xing Lyv; Gang Li; Chun-Yin Yan; Jian-Quan Hou; Jin-Xian Pu; Xiang Ding; Yu-Hua Huang
Journal:  Chin Med J (Engl)       Date:  2016-08-05       Impact factor: 2.628
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.